Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).
Hansoh Pharmaceutical Group Company Limited announced a license agreement with Glenmark Specialty S.A. for the development and commercialization of Aumolertinib in various global regions. This agreement, which includes upfront and potential milestone payments exceeding US$1 billion, along with tiered royalties, is expected to enhance Hansoh’s market presence and expand its reach in the oncology sector.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$48.20 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on innovative drug development. Its primary product, Aumolertinib, is a third-generation EGFR-TKI used for treating non-small cell lung cancer (NSCLC).
Average Trading Volume: 8,425,021
Technical Sentiment Signal: Buy
Current Market Cap: HK$260.4B
For a thorough assessment of 3692 stock, go to TipRanks’ Stock Analysis page.